12th Conference on Retroviruses and Opportunistic Infections Boston, Massachusetts - February 22-25, 2005

Conf Retrovir Opportunistic Infect 2005 Feb 22-25;12:abstract no. 40

Pablo Tebas¹, J Zhang², K Yarasheski³, S Evans², M Fischl⁴, A Shevitz⁵, J Feinberg⁶, A Collier⁷, C Shikuma⁸, B Brizz⁹, F Sattler¹⁰, and Adult AIDS Clinical Trials Group (AACTG)
¹Univ of Pennsylvania, Philadelphia, USA; ²Harvard Sch of Publ Hlth, Boston, MA, USA; ³Washington Univ, St Louis, MO, USA; ⁴Univ of Miami, FL, USA; ⁵Tufts Univ. School of Medicine, Boston, MA, USA; ⁶Univ of Cincinnati Med Ctr, OH, USA; ⁷Univ of Washington, Seattle, USA; ⁸Univ of Hawaii, Honolulu, USA; ⁹Social & Sci Systems, Inc, Silver Spring, MD, USA; and ¹⁰Univ of Southern California, Los Angeles, USA

BACKGROUND: Appendicular fat loss continues to be one the most troubling side effects of long term ART regimens. Therapeutic options for lipoatrophy remain limited. Nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimens are attractive potential alternatives to avoid toxicities associated with NRTI therapy.

METHODS: A5125s, the metabolic sub-study of A5116, examined the effects of NRTI-sparing and protease inhibitor (PI)-sparing regimens on fat distribution and bone mineral density; using whole body and regional DXA, and metabolic parameters in subjects with advanced HIV (nadir CD4 ≤ 200 cells/mm³ or HIV RNA ≥ 80,000 copies/mL) and undetectable HIV RNA ≤ 200 copies/mL after at least 18 months of ART, who were randomized to switch their initial successful antiretroviral regimen to open-label ritonavir-boosted lopinovir (LPV/r) (533/133 mg twice daily) + efavirenz (EFV) (600 mg once daily) vs EFV+2 NRTI.

RESULTS: We enrolled 62 subjects (85% men, 60% white). Median age was 42 years and median baseline CD4 was 432 cells/mm³ (p = ns). Median baseline appendicular fat was 6 kg. At week 48, median change in appendicular fat in the LPV/r+EFV arm was +562 g (IQR –218 to 1186 g) vs a loss of –246 g (–631 to 459 g) in the NRTI-containing arm (p = 0.097). At the time of last observation (n = 46, median 104 weeks) a median gain of 782 g (+10%, IQR –380 to 1168 g) of appendicular fat was noted in the non-NRTI arm vs a loss of –900 g (–15%, IQR –1301 to –466 g) in the NRTI-containing arm (p = 0.002). The study was not powered to detect differences between specific NRTI. At week 48, the LPV/r+EFV arm had greater increases in triglycerides (85 vs 11 mg/mL, p = 0.01) and in total cholesterol (+19 vs –7 mg/mL; p = 0.0008) compared with the NRTI arm. HDL cholesterol changes were similar (+6 mg/mL for LPV/r+EFV vs. +2 mg/ml for the NRTI- arm). There were no significant changes within each arm or differences between arms in fasting glucose, insulin and HOMA-IR levels. Trunk fat and bone mineral density remained stable.

CONCLUSIONS: The switch to a non-NRTI containing combination of LPV/r+EFV was associated with significant improvement in appendicular fat, increases in serum lipids, and stable glucose metabolism and regional bone mineral density. These findings support the observations that LPV/r has minimal effects on glucose metabolism, but is associated with greater increases in triglycerides and cholesterol than a NRTI-containing regimen. These results provide additional evidence that NRTI are important in progressive appendicular fat loss that characterizes HIV-lipoatrophy. The switch to a NRTI-sparing regimen represents a therapeutic option for patients with lipoatrophy.

050222
40

Copyright © 2005 - Foundation for Retrovirology and Human Health. Reproduction of this abstract (other than one copy for personal reference) must be cleared through the Foundation for Retrovirology and Human Health. Licensed (AIDSLINE) from National Library of Medicine.